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mucormycosis infection, in general, it stands to reason that it is an
infection that should be treated with prompt surgical debridement
as a general rule, especially in a transplant patient.1 In your com-
ments, you point out that your patient received vancomycin for
antibiotic prophylaxis prior to stent placement. Although there is
no consensus on this topic, we advocate prophylaxis in our review
for the initial stent placement and subsequent procedures that are
associated with transient bacteria, and cited hemodialysis and
immunosuppression as scenarios where other authors recom-
mended prophylaxis.2
With the increasing application of endovascular therapies and
the complexity of vascular patients, stent infection is a problem that
will only becomemore prevalent. We hoped to provide a thorough
review on the topic of bare metal stent infections; however, it is
possible that we may not have identified all publications on this
topic, as we are limited by search engines and key words. We
recently performed another query and identified a publication of
bare metal stent infection of the left external iliac artery that was
published a few weeks prior to the submission of our manuscript.6
While we did not include your report in our review, the underlying
message from your group and ours is the same. For anyone who
deploys bare metal stents, a high index of suspicion is needed in a
patient with a stent who presents with infectious symptoms and
prompt diagnosis and treatment is paramount to the patient’s
morbidity and survival.
Melissa E. Hogg, MD
Melina R. Kibbe, MD
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Regarding “Endoleaks after endovascular aneurysm
repair lead to nonuniform intra-aneurysm sac
pressure”
I read with interest the article by Dias et al1 describing the
measurement on intra-aneurysm sac pressure in patients with en-
doleaks post-endovascular aneurysm repair (EVAR) and congrat-
ulate the authors for their pioneering work in the area of sac
pressure measurement. However, I believe it necessary to chal-
lenge certain statements in the manuscript that apply to alternative
technologic approaches to long-term surveillance of EVAR pa-
tients.
In their article, the authors state that “the results of this study
show that the endoleak nidus (channel) has consistently higher
pressure than the intra-sac thrombus”. Their observations that the
pressure within the sac is nonuniform and that the pressure by the
endoleak nidus is higher than it would be within the thrombus are
consistent with previous clinical and experimental studies examin-
ing distribution of pressure resulting from an endoleak.2,3 It is
important to point out that attenuation of the pressure waveform
as it moves away from the source is a different physical phenomena
than what has been described as “compartmentalization”, which
suggests that there exist areas within the sac that are isolated from
the source of increased pressure. I believe the authors are blurring
this distinction and using this position to incorrectly conclude that
“this varying distribution of sac pressure in patients with en-
doleaks, although consistently higher in expanding AAAs, may
question the reliability of systems based on pressure measurements
in a single spot, such as with implantable pressure sensors”.
I have been closely involved with the development of implant-
able pressure sensors, which are being actively studied in multiple
areas of the body.4,5 Although the long-term data is still being
assembled, I strongly believe that Dias et al1 and Carpenter JP
(Commentary, J Vasc Surg 2007;46:203) are failing to note that
the fundamental difference between the work presented in this
manuscript and the use of permanently implanted sensors is that
themeasurements performed by the physicians inMalmo represent
a single moment, whereas the implantable sensors allow multiple
pressure readings to be taken over time, thus providing a history of
the sac’s pressure environment. The significance of this point is
that since, as Dias points out, sac pressure is elevated even in the
thrombus in the presence of an endoleak, serial measurements of
the sac, irrespective of the exact position of the sensor within the
sac, should allow the physician to prospectively see changes in
pressure that signal the stent graft may be in the process of failing.
This same conclusion could not be reached retrospectively with a
single measurement.
I believe that the use of implantable pressure measurement
systems will become an important tool in management of the
post-EVAR patient. Clinical trials to prove the long-term efficacy
of implantable pressure sensors are currently being designed and I
actively look forward to future reports detailing the chronic use of
these devices.
Takao Ohki, MD, PhD
Department of Surgery
Division of Vascular Surgery
Jikei University School of Medicine
Tokyo, Japan
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We thank Dr Ohki for his valuable comments on our article1
and appraise his unique contribution on the introduction of im-
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plantable pressure sensors. Our study is the first report on late
pressure measurements in the endoleak nidus (flow channel) and
the thrombus with the same technique and confirms a difference in
pressure gradient between these two locations. The previously
reported association of aneurysm shrinkage with intra-sac depres-
surization in the absence of endoleaks2 seems also to be present
with endoleaks. The degree of depressurization seems nevertheless
to be different. Pressure measurements in the presence of an
endoleak need, therefore, to be assessed cautiously, no matter how
the measurement was obtained.
Implantable pressure sensors have the advantage of allowing
repeated measurements over time.3,4 We share the view that pressure
sensorsmay eventually becomeuseful in the follow-upof patients after
EVAR. Before that happens, the aforementioned issues common to
all pressuremeasurement systems in the presence of endoleaks need to
be solved and the long-term accuracy of implantable sensors needs to
be established. Implantable devices have been validated in the imme-
diate period after EVAR, but thrombus can change with time acquir-
ing a non-uniform structure5-7 that can influence transmission of
pressure.8,9 Some of these issues are expected to be answered by
on-going trials, which will hopefully include a validation against the
validated direct intra-aneurysm sac pressure measurements (DISP)
with tip-pressure sensors.
Nuno V. Dias, MD, PhD
Krassi Ivancev, MD, PhD
Timothy A. Resch, MD, PhD
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Regarding “Does simvastatin save lives; If so, when
and in whom?”
In theHeart Protection Study,1 it was suggested that cholesterol-
lowering therapy with simvastatin can reduce the risk of major
vascular events among people with peripheral artery disease
(PAD). However, a clearly defined effect on total mortality was not
reported. In 1992, four of the initiators of the Heart Protection
Study (HPS) called for larger total mortality trials to generate data
in six named patient subgroups.2 In 2001, after their study was
completed, the press release started with the words “LIFE-SAVER”
but it gave no data on deaths.3 Similarly, the current HPS report
avoided the subject by curiously combining deaths with aneurysm
repairs, only to find a small increase on simvastatin for this com-
bined endpoint.
Furthermore, HPS found no significant mortality benefit in
women, and it now seems that this could also be true for patients
with baseline PAD.1 The authors admitted that much of their
combined endpoint event benefit in PAD patients was in revascu-
larizations, and after they retrospectively redefined “peripheral
vascular events” to include all noncardiac revascularizations includ-
ing carotid procedures.
Revascularizations are procedures that may or may not affect
mortality or future cardiovascular events,4 and it is, thus, important
to report deaths and true disease endpoints separately. Regardless,
despite the absence of noncombined endpoint numbers and num-
bers needed to treat, the article and its debating author, Dr
Bulbulia, stated repeatedly that patients with PAD “should be” on
statin (presumably for life) and that there “should be no threshold for
initiation of statin therapy”.1 We believe that this is not supported
by the grouped endpoint data presented, especially since total
deaths are not clearly reported for all participant groups.
Interestingly, HPS, 4S5 and LIPID6 are the only three large
statin trials to show a brief period of mortality benefit, almost
certainly in some men only. Such benefit appeared after about 1.5
years of use and ended about 2 or 3 years later. Such time-
dependent and time-limited mortality effect can be shown by
releasing the relevant disease and group specific time curves indi-
vidually.
The authors of HPS should therefore finally release a table for
total deaths, heart attacks, amputations, and other disease end-
points and related numbers needed to treat, with confidence levels,
in women, men, and diabetics, and in this case for PAD patients for
1, 3, and 5 years of simvastatin treatment regarding these end-
points. Without such curves and year-by-year disease and group
specific numbers needed to treat, prescribers lack crucial data
relevant to their patients. Patients deserve to be told their odds of
avoiding death and each of the various lesser disease endpoints and
for how long they need to take statin to attain these results, and
when the effect may no longer exist or be incremental.
Eddie Vos, M. Eng
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